Pretreatment characteristics and outcome of APL patients included in the joint analysis
| Characteristics . | LPA 99 trial, N = 410 . | APL 2000 trial, N = 178 . | P . | Adjusted P* . |
|---|---|---|---|---|
| Age, y, median (Q1-Q3) | 37 (24-49) | 43 (29-51) | .016 | — |
| Age younger than 60 y, no. (%) | 378 (92.2) | 167 (93.8) | .60 | — |
| Male sex, no. (%) | 200 (48.8) | 80 (44.9) | .42 | — |
| WBC count, 109/L, median (Q1-Q3) | 2.5 (1.2-10.5) | 7.1 (1.5-27.5) | < .001 | — |
| Platelet count, 109/L, median (Q1-Q3) | 22 (13-38) | 32 (19-58) | <.001 | — |
| Fibrinogen level, g/L, median (Q1-Q3) | 1.5 (1.0-2.3) | 1.5 (1.0-2.4) | .97 | — |
| Sanz score, no. (%) | ||||
| Low risk | 73 (17.8) | 43 (24.2) | <.001 | — |
| Intermediate risk | 233 (56.8) | 53 (29.8) | — | — |
| High risk | 104 (25.4) | 82 (46.0) | — | — |
| Complete remission, no. (%) | 381 (92.9) | 173 (97.2) | .053 | .018 |
| Deaths in CR, no. (%) | 5/381 (1.3) | 5/173 (2.9) | .049 | .18 |
| Relapses, no. (3-y cumulative incidence, %) | 33/381 (7.4) | 16/173 (12.0) | .32 | .33 |
| Total events, no. (3-y EFS, %) | 66 (85.3) | 26 (86) | .97 | .81 |
| Total deaths, no. (3-y OS, %) | 43 (90.5) | 11 (93.7) | .14 | .086 |
| Characteristics . | LPA 99 trial, N = 410 . | APL 2000 trial, N = 178 . | P . | Adjusted P* . |
|---|---|---|---|---|
| Age, y, median (Q1-Q3) | 37 (24-49) | 43 (29-51) | .016 | — |
| Age younger than 60 y, no. (%) | 378 (92.2) | 167 (93.8) | .60 | — |
| Male sex, no. (%) | 200 (48.8) | 80 (44.9) | .42 | — |
| WBC count, 109/L, median (Q1-Q3) | 2.5 (1.2-10.5) | 7.1 (1.5-27.5) | < .001 | — |
| Platelet count, 109/L, median (Q1-Q3) | 22 (13-38) | 32 (19-58) | <.001 | — |
| Fibrinogen level, g/L, median (Q1-Q3) | 1.5 (1.0-2.3) | 1.5 (1.0-2.4) | .97 | — |
| Sanz score, no. (%) | ||||
| Low risk | 73 (17.8) | 43 (24.2) | <.001 | — |
| Intermediate risk | 233 (56.8) | 53 (29.8) | — | — |
| High risk | 104 (25.4) | 82 (46.0) | — | — |
| Complete remission, no. (%) | 381 (92.9) | 173 (97.2) | .053 | .018 |
| Deaths in CR, no. (%) | 5/381 (1.3) | 5/173 (2.9) | .049 | .18 |
| Relapses, no. (3-y cumulative incidence, %) | 33/381 (7.4) | 16/173 (12.0) | .32 | .33 |
| Total events, no. (3-y EFS, %) | 66 (85.3) | 26 (86) | .97 | .81 |
| Total deaths, no. (3-y OS, %) | 43 (90.5) | 11 (93.7) | .14 | .086 |
— indicates not applicable.
Adjusted for age, sex, WBC count, and platelet count.